Contact
Please use this form to send email to PR contact of this press release:
Forty Seven, Inc. Announces Updated Initial Data from Phase 1b Clinical Trial of 5F9 in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
TO: